| /C O R R E C T I O N -- Bristol-Myers Squibb and AstraZeneca/ - PR Newswire (press release) |
|
|
PR Newswire (press release) ONGLYZA is not recommended for patients with end-stage renal disease (ESRD) requiring hemodialysis. ONGLYZA has been submitted for regulatory review in more than 87 countries and is approved in 56 countries, including the United States, Canada, Mexico, |